AkzoNobel Says Two Sales Are the Only Remedies Regulators Want for the $25 Billion Axalta Merger

The remedy list for one of the coatings industry's biggest mergers now fits on an index card — and, on the chief executive's account, it is not getting longer.

Two coatings makers trying to become one now say the price of approval is two businesses — and nothing more. On Wednesday, Oct. 21, AkzoNobel Chief Executive Greg Poux-Guillaume said regulators reviewing the $25 billion combination with Axalta have asked for exactly two divestitures: AkzoNobel's vehicle refinishing operation in Europe and the Axalta business the Oct. 21 reporting describes as its United States wood finishes unit.

"There's no regulator anywhere that has asked us to do anything else in terms of remedies," Poux-Guillaume said. The pair of sales is aimed at two specific clearances: approval from the United States Federal Trade Commission, and Phase 1 clearance in Europe. If both land as he expects, the companies still plan to complete the merger early in 2027, the timetable they have given all along.

The filing gives the Axalta sale its formal name

Axalta put its side of the remedy into the public record a day earlier. In a Form 425 filed with the United States Securities and Exchange Commission on Tuesday, Oct. 20, Axalta said it is planning for the divestiture of its North American Building Products business as part of the regulatory approval process, and that the expected divestiture is intended to address regulatory requirements and support completion of the merger.

The two descriptions need care rather than blending. The filing's own name for the business is North American Building Products, while the Oct. 21 reporting describes the Axalta operation as its United States wood finishes business. This article uses the filing's name for the planned divestiture and does not treat the two labels as proof of identical scope, because neither document establishes that they cover exactly the same ground.

What the filing does establish is the reason and the human terms. Axalta said the expected divestiture is driven by merger regulatory requirements, rather than business performance, called Building Products a strong business, and said there are no immediate changes to employees' roles, reporting relationships or day-to-day responsibilities as a result of the announcement. The filing also said the merger remains on track to close in the first quarter of 2027, subject to remaining regulatory approvals and other customary closing conditions.

Commitments in Brussels, a decision due in November

The European leg is already further along than a promise. The companies submitted commitments to the European Commission on Oct. 15, extending the preliminary review into November, and the Commission has not publicly disclosed the contents of those commitments. A Commission filing on Friday showed remedies had been offered to secure approval, without disclosing the details.

The next dated test is close. The European antitrust decision is expected in November, according to analysts at Jefferies cited in the Oct. 21 reporting. Earlier in October, reporting citing people familiar with the matter said the companies were set to win European antitrust approval with a pledge to sell AkzoNobel's vehicle refinish business — the same business now named on the record by the chief executive as one of only two remedies.

The deal being defended is an all-stock merger. AkzoNobel pressed ahead with it after rejecting a 12.5 billion euro cash bid from Nippon Paint and Sherwin-Williams in May, a bid it said undervalued the business and would have split it between the two suitors.

A steady quarter underneath the deal work

The comments came on the same morning AkzoNobel published third-quarter results, and the results gave the deal narrative a calm backdrop. Adjusted earnings for the quarter were 388 million euros. A year earlier the same measure was 385 million euros, and the consensus AkzoNobel itself compiled had pointed to 387 million euros, so the print landed a touch ahead of expectations, helped by firmer pricing and the company's cost programme. Profitability edged up, with the adjusted margin at 15.3% against 15.1% a year earlier, and management left its full-year 2026 adjusted earnings guide untouched at 1.47 billion euros, with the chief executive calling the merger firmly on track. None of that alters the merger arithmetic; it simply means AkzoNobel heads into the November decision without a guidance problem of its own making.

What to watch, and what is still unknown

Two approvals now decide the timetable. The European decision expected in November will show whether the commitments offered on Oct. 15 are enough for Phase 1 clearance, and the Federal Trade Commission's decision will show whether the North American Building Products divestiture closes the United States file as the chief executive expects. What remains unknown is precise: no buyer has been named for either business, no sale price has been disclosed for either remedy, the contents of the Brussels commitments have not been made public, and neither approval has been granted yet. The closing guide is unchanged — early 2027 on the chief executive's account, the first quarter of 2027 in Axalta's filing — but it stays a guide until both regulators have actually decided.